Biomarker: ATAD2

Histology type: endometrial carcinoma

Country: Norway

Region: Bergen

Study type: Prospective study.

Followed up time :

Subgroup 1 name : low

Subgroup 1 number: 281

Subgroup 2 name: high

Subgroup 2 number: 283

Conclusion: Our results support that IHC staining for ATAD2 may be a clinically applicable biomarker reflecting clinical phenotype and targetable alterations in endometrial carcinomas to be further explored in controlled clinical trials.

Sample type : tissue

Sample method: immunohistochemical (IHC) staining

Expression pattern : overexpression(index 3-9)

Expression elevation: A staining index was calculated as a product of staining intensity (0-3) and area of positive tumor cells (1≤10%, 2 = 10-50% and 3≥50%). In subsequent statistical analyses, indexes were grouped according to similarity in survival and considering the size of the subgroups and the number of events in each category. Index 0-2 (n = 281) was considered low, index 3-9 (n = 283) was considered high.

Statictics: cutoff<66;cutoff>66

Cohort age: 294;270

Subgroup 1 age: 156;125

Subgroup 2 age: 138;145

Funtion Uniprot: May be a transcriptional coactivator of the nuclear receptor ESR1 required to induce the expression of a subset of estradiol target genes, such as CCND1, MYC and E2F1. May play a role in the recruitment or occupancy of CREBBP at some ESR1 target gene promoters. May be required for histone hyperacetylation. Involved in the estrogen-induced cell proliferation and cell cycle progression of breast cancer cells.

UniProt ID: Q6PL18

UniProt Link: https://www.uniprot.org/uniprotkb/Q6PL18/entry

Biological function from UniProt: #Transcription #Transcription regulation

Molecular function from UniProt:

Tissue specificity from UniProt: Highly expressed in estrogen receptor positive breast tumors and in osteosarcoma tumors.

Subcellular UniProt: #Nucleus

Alternative name from UniProt:

Catalytic activity: ATP + H2O = ADP + H+ + phosphate

Recommended name: ATPase family AAA domain-containing protein 2

Gene name from HGNC: ATAD2 (ANCCA, CT137, DKFZp667N1320, MGC29843, MGC5254, PRO2000)

AlphaFold DB: Q6PL18

AlphaFold Link: https://alphafold.ebi.ac.uk/entry/Q6PL18

Induction: Up-regulated in breast, uterus, colon, ovary, and stomach tumors. Induced in breast cancer cells overexpressing NCOA3 or treated with estrogen. Down-regulated in 5-fluorouracil-resistant derivatives of the colon cancer cell line HCT 116.

HPA link: https://www.proteinatlas.org/ENSG00000156802-ATAD2

Tissue specificity RNA from HPA: Tissue enhanced (lymphoid tissue)

Tissue expression from HPA: Nuclear expression in proliferating cells.

Single cell type specificity Cell type enhanced (Spermatocytes, Spermatogonia, Erythroid cells)

Immune cell specificity: Low immune cell specificity

Subcellular summary HPA Located in Nucleoplasm (Single cell variability, CCD Protein, CCD Transcript)

Cancer prognostic summary HPA Prognostic marker in renal cancer (unfavorable) and endometrial cancer (unfavorable)

Pathology link: https://www.proteinatlas.org/ENSG00000156802-ATAD2/pathology

Pathology endo: https://www.proteinatlas.org/ENSG00000156802-ATAD2/pathology/endometrial+cancer

Expression figure legend: Immunohistochemical detection of ATAD2 protein in endometrial carcinomas

Expression figure link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695070/figure/F2/

Survival figure legend: ATAD2 predicts poor prognosis in endometrial cancer $ ATAD2 is a prognostic marker in subgroups of endometrial cancer

Survival curve link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695070/figure/F3/$https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695070/figure/F4/?report=objectonly

OMIM: 611941

OMIM link2: https://www.omim.org/entry/611941

HGNC ID: HGNC:30123

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30123